Idiopathic Parkinson Disease Clinical Trial
Official title:
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Verified date | January 2017 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.
Status | Completed |
Enrollment | 18 |
Est. completion date | March 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 85 Years |
Eligibility | Inclusion Criteria: - L-DOPA-responsiveness - Hoehn & Yahr Stage II-III inclusive - Experiencing motor fluctuations - Stable daily dose of L-DOPA of at least 300 mg - Females on non-childbearing potential and male subjects Exclusion Criteria: - History of troublesome dyskinesias - History of surgical intervention for Parkinson's disease |
Country | Name | City | State |
---|---|---|---|
Belgium | Pfizer Clinical Research Unit | Brussels | |
United States | Atlanta Center for Medical Research | Atlanta | Georgia |
United States | SNBL Clinical Pharmacology Center, Inc. | Baltimore | Maryland |
United States | Neurology Consultants of Dallas, PA | Dallas | Texas |
United States | Walnut Hill Medical Center | Dallas | Texas |
United States | Parkinson's Movement Disorder Center of Maryland | Elkridge | Maryland |
United States | MD Clinical | Hallandale Beach | Florida |
United States | Collaborative Neuroscience Network, LLC. | Long Beach | California |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number and proportion of subjects with Adverse Events (AEs) | Day 1 through 61 | ||
Primary | Number of participants with vital signs data that meet criteria of potential clinical concern | Day 1 through 61 | ||
Primary | Number of participants with ECG data that meet criteria of potential clinical concern | Day 1 through 61 | ||
Primary | Number of participants with abnormal clinically significant laboratory measurements | Day 1 through 61 | ||
Primary | C-SSRS (suicidality assessment) | Day 1 through 61 | ||
Secondary | MDS-UPDRS part III | MDS - Unified Parkinson's Disease Rating Scale Part III | Day 1, Periods 1-3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04202757 -
Intravenous Plasma Treatment for Parkinson's Disease
|
Early Phase 1 | |
Not yet recruiting |
NCT05103618 -
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
|
Phase 2 | |
Completed |
NCT03700684 -
Voice Treatment for Parkinson's Disease
|
N/A | |
Completed |
NCT05027620 -
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
|
N/A | |
Completed |
NCT03652363 -
GDNF in ideopathicParkinsons Disease
|
Phase 2 | |
Recruiting |
NCT02960464 -
tDCS for Treatment of Depression in Parkinson's Disease
|
N/A | |
Completed |
NCT05699161 -
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
|
Phase 1/Phase 2 | |
Completed |
NCT03944785 -
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
|
||
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Terminated |
NCT01215227 -
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
|
Phase 3 | |
Withdrawn |
NCT05832775 -
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
|
Phase 1 | |
Active, not recruiting |
NCT02780895 -
Parkinsonian Brain Repair Using Human Stem Cells
|
Phase 1 | |
Recruiting |
NCT01860794 -
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02393027 -
Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
|
Early Phase 1 | |
Completed |
NCT02445651 -
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT00437125 -
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
|
Phase 4 | |
Completed |
NCT02723396 -
Sleep, Awake & Move - Part I
|
||
Completed |
NCT00599339 -
Transdermal Rotigotine User Surveillance Study
|
||
Suspended |
NCT05471609 -
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
|
Early Phase 1 | |
Completed |
NCT00160576 -
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
|
Phase 2 |